D.E. Shaw & Co
AIMT

D.E. Shaw & Co’s Aimmune Therapeutics AIMT Stock Holding History

D.E. Shaw & Co’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-15,530
Closed -$535K – 4314
2020
Q3 		$535K Sell
15,530
-141,818
-90% -$3.02M ﹤0.01% 3198
2020
Q2 		$2.63M Buy
157,348
+145,148
+1,190% +$2.46M ﹤0.01% 2180
2020
Q1 		$176K Sell
12,200
-19,115
-61% -$489K ﹤0.01% 3684
2019
Q4 		$1.05M Buy
+31,315
New +$875K ﹤0.01% 2948
2016
Q3 		– Sell
-19,849
Closed -$215K – 3634
2016
Q2 		$215K Buy
+19,849
New +$270K ﹤0.01% 3166

D.E. Shaw & Co's AIMT Position: Q4 2020 in Review

D.E. Shaw & Co sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 15,530 shares — an estimated $535K sold.

D.E. Shaw & Co first reported a position in AIMT in Q2 2016 and held it in 5 quarters. The position peaked at $2.63M in Q2 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • D.E. Shaw & Co reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • D.E. Shaw & Co sold 15,530 Aimmune Therapeutics shares in Q4 2020, an estimated $535K.
  • D.E. Shaw & Co first reported a position in Aimmune Therapeutics in Q2 2016 and held it in 5 quarters.
  • D.E. Shaw & Co's Aimmune Therapeutics position peaked at $2.63M in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on D.E. Shaw & Co's 13F filing for Q4 2020, filed 16 Feb 2021.